Resumption of Intravenous Anti-Cancer Therapy in Breast Cancer: A Real-World Experience During the SARS-CoV-2 Pandemic.

Fang YangCong LiYuling QiuXinjie ChenKelin ZhengDonglin KangYin ZhangBaorui LiuYongzhong YaoLi Xie

Published in: Cancer management and research (2024)

Our findings reveal that the SARS-CoV-2 infection led to imbalanced immune responses and postponed intravenous anti-cancer therapy in breast cancer. The safety report encourages timely resumption of intravenous anti-cancer therapy after adequately weighing the risks and benefits.

Keyphrases

cancer therapy
sars cov
drug delivery
high dose
immune response
coronavirus disease
gene expression
single cell
dendritic cells
climate change
inflammatory response